Warfarin Toxicity and Individual Variability—Clinical Case
2010
Warfarin Toxicity and Individual Variability
Sample size: 1
publication
Evidence: low
Author Information
Author(s): Irina Piatkov, Colin Rochester, Trudi Jones, Steven Boyages
Primary Institution: Diversity Health Institute, DHI Laboratory, ICPMR
Hypothesis
Can genetic testing improve the safety and effectiveness of warfarin treatment?
Conclusion
Genetic testing can help identify patients at risk for warfarin toxicity and guide safer dosing.
Supporting Evidence
- Genetic factors and drug interactions mostly account for the risk of over-anticoagulation.
- Patients with CYP2C9 polymorphisms require lower warfarin doses to avoid bleeding complications.
- Concurrent use of SSRIs with warfarin increases the risk of bleeding.
Takeaway
Some people react differently to warfarin because of their genes, and testing can help doctors give the right amount to avoid problems.
Methodology
The study involved a case report of a patient with deep vein thrombosis and genetic testing for CYP2C9 polymorphisms.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
The patient was a 50-year-old woman.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website